1. Evaluation of Bifidobacterium and Anti-PD-1 Combination Therapy in a Mouse Intracerebral Melanoma Metastasis Model.
- Author
-
SÖYLER, Sena Nur and HATİBOĞLU, Mustafa Aziz
- Subjects
- *
BIFIDOBACTERIUM , *IMMUNE checkpoint inhibitors , *BRAIN metastasis , *METASTASIS , *GUT microbiome , *MELANOMA - Abstract
Introduction: The discovery of the relationship between immune checkpoint inhibitors (ICI) and gut microbiota has highlighted gut microbiota as a potential biomarker and therapeutic target for ICI treatment. In this study, the effectiveness of anti-PD-1 (programed cell death protein) treatment in brain tumor-bearing mice treated with antibiotics and Bifidobacterium will be examined. Method: Mice in the antibiotic group were treated with broad-spectrum antibiotics before tumor implantation. Mice in the treatment group received 5 doses of anti-PD1 intraperitoneally. Bifidobacterium is administered to mice by oral gavage for 7 doses. Mice were monitored daily after tumor implantation and sacrificed when they met the euthanasia criteria. Results: Antibiotic-treated mice (group 2) did not show a significant increase in survival rates when they received anti-PD1 (group 4) (mean survival days: Abx 15±0.6; Abx + anti-PD1 17±0.9). However, antibiotic-treated mice showed a significant increase in survival rates when they received both anti-PD1 and Bifidobacterium (group 5) when compared to only antibiotic-treated mice (group 2) (mean survival days: Abx 15±0.6; Abx + anti-PD1 + bifido 18±0.5, p<0.005 by t-test). Conclusion: The effect of intestinal microbiota on anti-PD1 treatment response was examined for the first time in a melanoma brain metastasis model. The results of our study show that gut microbiota can influence immunotherapy response in melanoma brain metastasis. [ABSTRACT FROM AUTHOR]
- Published
- 2024